MX2015007916A - Peri-carbinoles. - Google Patents
Peri-carbinoles.Info
- Publication number
- MX2015007916A MX2015007916A MX2015007916A MX2015007916A MX2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A MX 2015007916 A MX2015007916 A MX 2015007916A
- Authority
- MX
- Mexico
- Prior art keywords
- carbinols
- peri
- reducing
- symptom
- risk
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740197P | 2012-12-20 | 2012-12-20 | |
| PCT/US2013/076592 WO2014100425A1 (en) | 2012-12-20 | 2013-12-19 | Peri-carbinols |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007916A true MX2015007916A (es) | 2016-04-07 |
Family
ID=50979217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007916A MX2015007916A (es) | 2012-12-20 | 2013-12-19 | Peri-carbinoles. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9604997B2 (enExample) |
| EP (1) | EP2935220A4 (enExample) |
| JP (1) | JP2016503797A (enExample) |
| KR (1) | KR20150118106A (enExample) |
| CN (1) | CN105073714A (enExample) |
| AU (1) | AU2013361314A1 (enExample) |
| CA (1) | CA2896032A1 (enExample) |
| CL (1) | CL2015001754A1 (enExample) |
| HK (1) | HK1217325A1 (enExample) |
| IL (1) | IL239178A0 (enExample) |
| MX (1) | MX2015007916A (enExample) |
| RU (1) | RU2015120478A (enExample) |
| SG (1) | SG11201504859YA (enExample) |
| WO (1) | WO2014100425A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN110684067A (zh) | 2012-12-21 | 2020-01-14 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸 |
| SG11201505587YA (en) | 2013-01-23 | 2015-08-28 | Aldeyra Therapeutics Inc | Toxic aldehyde related diseases and treatment |
| CA2898869A1 (en) | 2013-01-25 | 2014-07-31 | Aldeyra Therapeutics, Inc. | Novel traps in the treatment of macular degeneration |
| AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| HK1256143A1 (zh) * | 2015-08-21 | 2019-09-13 | Aldeyra Therapeutics, Inc. | 醛结合物和其用途 |
| EP3419633A4 (en) | 2016-02-28 | 2019-10-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF ALLERGIC EYE DISEASES WITH CYCLODEXTRINS |
| WO2017196881A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| WO2018039192A1 (en) * | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
| CA3054811A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| JP7706758B2 (ja) | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
| CN116157387A (zh) | 2020-07-16 | 2023-05-23 | 德玛万科学有限公司 | 异喹啉化合物及其在治疗AhR失衡中的用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| CN1228084A (zh) | 1996-08-01 | 1999-09-08 | 道农业科学公司 | 具有杀菌活性的4－取代的喹啉衍生物 |
| EP0980362B1 (de) | 1997-05-02 | 2006-08-16 | Schering Aktiengesellschaft | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| WO1999046237A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| WO2001041757A1 (en) | 1999-12-10 | 2001-06-14 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP3326623A1 (en) | 2003-03-14 | 2018-05-30 | University of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| DE602004030103D1 (de) | 2003-04-18 | 2010-12-30 | Advanced Medicine Res Inst | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US7563906B2 (en) | 2003-10-15 | 2009-07-21 | Ube Industries, Ltd. | Indazole derivatives |
| AU2004293105B2 (en) | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| EP1722766A2 (en) | 2004-02-17 | 2006-11-22 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| CN101048384A (zh) * | 2004-10-28 | 2007-10-03 | 默克公司 | 促代谢型谷氨酸盐受体的嘧啶和喹啉增效剂 |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| US20100144693A1 (en) * | 2006-04-14 | 2010-06-10 | Prana Biotechnology Limited | Method of treatment of age-related macular degeneration (amd) |
| RU2009106461A (ru) | 2006-07-25 | 2010-08-27 | Энвиво Фармасьютикалз, Инк. (Us) | Хинолиновые производные |
| WO2009045479A1 (en) | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
| MX2011001702A (es) | 2008-08-12 | 2011-04-28 | Sirtris Pharmaceuticals Inc | Benzoxazoles, benzotiazoles y analogos relacionados como moduladores de sirtuina. |
| WO2010133672A1 (en) * | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| EP2477594A4 (en) | 2009-07-15 | 2013-03-13 | Univ Vanderbilt | ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| BR112013017943A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores receptores do tipo toll |
| CN103442735B (zh) | 2011-01-31 | 2016-11-09 | 特米拉公司 | 用于减轻技术领域中所不希望的医学状况的有效要素 |
| SG11201505587YA (en) | 2013-01-23 | 2015-08-28 | Aldeyra Therapeutics Inc | Toxic aldehyde related diseases and treatment |
| CA2898869A1 (en) | 2013-01-25 | 2014-07-31 | Aldeyra Therapeutics, Inc. | Novel traps in the treatment of macular degeneration |
| US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| WO2016085939A2 (en) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
-
2013
- 2013-12-19 HK HK16105238.3A patent/HK1217325A1/zh unknown
- 2013-12-19 CA CA2896032A patent/CA2896032A1/en not_active Abandoned
- 2013-12-19 JP JP2015549717A patent/JP2016503797A/ja not_active Withdrawn
- 2013-12-19 US US14/653,771 patent/US9604997B2/en active Active
- 2013-12-19 CN CN201380067618.3A patent/CN105073714A/zh active Pending
- 2013-12-19 EP EP13865015.5A patent/EP2935220A4/en not_active Withdrawn
- 2013-12-19 MX MX2015007916A patent/MX2015007916A/es unknown
- 2013-12-19 SG SG11201504859YA patent/SG11201504859YA/en unknown
- 2013-12-19 KR KR1020157019397A patent/KR20150118106A/ko not_active Withdrawn
- 2013-12-19 WO PCT/US2013/076592 patent/WO2014100425A1/en not_active Ceased
- 2013-12-19 RU RU2015120478A patent/RU2015120478A/ru unknown
- 2013-12-19 AU AU2013361314A patent/AU2013361314A1/en not_active Abandoned
-
2015
- 2015-06-03 IL IL239178A patent/IL239178A0/en unknown
- 2015-06-18 CL CL2015001754A patent/CL2015001754A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014100425A1 (en) | 2014-06-26 |
| EP2935220A1 (en) | 2015-10-28 |
| JP2016503797A (ja) | 2016-02-08 |
| CL2015001754A1 (es) | 2015-11-06 |
| HK1217325A1 (zh) | 2017-01-06 |
| KR20150118106A (ko) | 2015-10-21 |
| RU2015120478A (ru) | 2017-01-25 |
| CN105073714A (zh) | 2015-11-18 |
| US20150344432A1 (en) | 2015-12-03 |
| EP2935220A4 (en) | 2016-04-27 |
| CA2896032A1 (en) | 2014-06-26 |
| SG11201504859YA (en) | 2015-07-30 |
| IL239178A0 (en) | 2015-07-30 |
| AU2013361314A1 (en) | 2015-07-02 |
| US9604997B2 (en) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007916A (es) | Peri-carbinoles. | |
| MX2015009444A (es) | Trampas novedosas en el tratamiento de la degeneracion macular. | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| IN2015DN01156A (enExample) | ||
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| PH12015501385A1 (en) | Autotaxin inhibitors | |
| PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| MX2015012478A (es) | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. | |
| MD20150048A2 (ro) | Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K | |
| IN2015DN01151A (enExample) | ||
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| GEP20207108B (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| MX362879B (es) | Usos novedosos. | |
| PH12014501712B1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
| MX2014013758A (es) | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. | |
| MX364528B (es) | Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX365315B (es) | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| IN2014DN08443A (enExample) | ||
| MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
| EA033160B1 (ru) | Соединения для лечения заболеваний, связанных с ишемией-реперфузией | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| IN2014DN10683A (enExample) | ||
| NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy |